The Patent Finder

Domantis Limited

6 patents currently held · Updated Nov 22, 2026
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Sep 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jul 5 to 28, 2027 · next Jul 5

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,236,931Prevention of aggregation of immunoglobulin light or heavy chains
In force
 · USPTO record
In forceUSPTO record
US 8,357,780Polypeptides, antibody variable domains and antagonists methods for
In force
 · USPTO record
In forceUSPTO record
US 8,921,528Bispecific fusion antibodies with enhanced serum half-life
In force
 · USPTO record
In forceUSPTO record
US 9,228,018Antibody Polypeptides That Antagonize CD40L
In force
 · High confidence
In forceHigh confidence
US 10,544,228Nucleic Acids Encoding Antibody Polypeptides That Antagonize CD40
In force
 · Medium confidence
In forceMedium confidence
US 9,475,879Antibody polypeptides that antagonize CD40
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 6: 9 patents in force now held by others · 21 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 abandoned · 44 no status recorded

Showing 1 to 10 of 47, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
17/522,008Antibody Polypeptides That Antagonize CD40LNov 9, 2021Abandoned
16/047,197Polypeptides, Antibody Variable Domains & AntagonistsJul 27, 2018Abandoned
15/469,839Mar 27, 2017No status recorded
14/924,971Oct 28, 2015No status recorded
14/540,108Nov 13, 2014No status recorded
14/159,791Jun 20, 2014No status recorded
14/173,204Feb 5, 2014No status recorded
13/733,675Jan 3, 2013No status recorded
13/644,414Oct 26, 2012No status recorded
13/545,795Jul 10, 2012No status recorded
10 of 47 applications shown.
Pro members see all 47 published applications.
Pro members: see all 47 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited